Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Rodrigues CSMA, A. Epigenetic Regulators as the Gatekeepers of Hematopoiesis. Trends in Genetics In press.
- The role of mutations in epigenetic regulators in myeloid malignancies.Nat Rev Cancer. 2012; 12: 599-612
- Clonal hematopoiesis and evolution to hematopoietic malignancies.Cell Stem Cell. 2018; 22: 157-170
- Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371: 2488-2498
- The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis.Blood. 2018; 131: 2111-2119
- Mechanisms and consequences of Jak-STAT signaling in the immune system.Nat Immunol. 2017; 18: 374-384
- JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.Nature. 2009; 461: 819-822
- PRMT5 function and targeting in cancer.Cell Stress. 2020; 4: 199-215
- JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.Cancer Cell. 2011; 19: 283-294
- Cytokine-regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis.Cancer Discov. 2019; 9: 778-795
- Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.Cancer Res. 2013; 73: 1076-1085
- Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.Haematologica. 2013; 98: 1414-1420
- Epigenetic changes in myelofibrosis: distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.Sci Rep. 2017; 7: 6774
- The role of ASXL1 in hematopoiesis and myeloid malignancies.Cell Mol Life Sci. 2019; 76: 2511-2523
- Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated.Haematologica. 2019; 104: 1572-1579
- Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms.Cancer Cell. 2018; 33: 29-43 e7
- Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses.Cancers (Basel). 2020; 12: 2194
- Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues.Cancers (Basel). 2020; 12: 2216
- Targeted deep sequencing in primary myelofibrosis.Blood Adv. 2016; 1: 105-111
- Mutations and prognosis in primary myelofibrosis.Leukemia. 2013; 27: 1861-1869
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.Leukemia. 2010; 24: 1302-1309
- Classification and personalized prognosis in myeloproliferative neoplasms.N Engl J Med. 2018; 379: 1416-1430
- Targeted deep sequencing in polycythemia vera and essential thrombocythemia.Blood Adv. 2016; 1: 21-30
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.Leukemia. 2014; 28: 1804-1810
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Blood. 2015; 126: 790-797
- Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.Blood Adv. 2017; 1: 1729-1738
- Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2017; 23: 1095-1101
- Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis.Biol Blood Marrow Transplant. 2019; 25: 1142-1151
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.Blood. 2014; 123: 2220-2228
- Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.N Engl J Med. 2010; 362: 369-370
- IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.Leukemia. 2010; 24: 1146-1151
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.Leukemia. 2012; 26: 475-480
- Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing.Mol Cell. 2019; 73: 1292-1305.e8
- Effect of mutation order on myeloproliferative neoplasms.N Engl J Med. 2015; 372: 601-612
- Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.Blood. 2015; 125: 304-315
- Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.Blood. 2015; 125: 327-335
- Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self- renewal.Blood. 2018; 132: 791-803
- Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.Blood. 2018; 132: 2707-2721
- Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.Genes Chromosomes Cancer. 2012; 51: 743-755
- The role of IDH mutations in acute myeloid leukemia.Future Oncol. 2018; 14: 979-993
- JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.J Clin Invest. 2018; 128: 789-804
- Polycomb silencers control cell fate, development and cancer.Nat Rev Cancer. 2006; 6: 846-856
- The Polycomb group protein EZH2 directly controls DNA methylation.Nature. 2006; 439: 871-874
- The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.J Exp Med. 2016; 213: 1459-1477
- Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.J Exp Med. 2016; 213: 1479-1496
- Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.Blood. 2016; 127: 3410-3423
- ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.Cancer Cell. 2012; 22: 180-193
- Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.J Exp Med. 2013; 210: 2641-2659
- The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.J Hematol Oncol. 2017; 10: 139
- Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.J Exp Med. 2018; 215: 1729-1747
- Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.Leukemia. 2019; 33: 191-204
- Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.Blood. 2018; 131: 328-341
- ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.Leukemia. 2019; 33: 1287-1291
- DNA hypomethylating drugs in cancer therapy.Cold Spring Harb Perspect Med. 2017; 7: a026948
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.Leukemia. 2008; 22: 965-970
- Leukemia secondary to myeloproliferative neoplasms.Blood. 2020; 136: 61-70
- A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Blood. 2018; 132: 1664-1674
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med. 2012; 366: 799-807
- BET proteins as targets for anticancer treatment.Cancer Discov. 2018; 8: 24-36
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.Leukemia. 2017; 31: 678-687
- CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: update of MANIFEST phase 2 study.American Society of Hematology, Virtual2020
- CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to JAK inhibitor: update from phase 2 MANIFEST study.American Society of Hematology, Virtual2020
- Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation.Leukemia. 2012; 26: 2039-2051
- Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms.Blood. 2014; 124: 151-152
- LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone.Hemasphere. 2018; 2: e54
- A phase 2 study of the LSD1 inhibitor IMG7289 (bomedemstat) for the treatment of advanced myelofibrosis.American Society of Hematology, Virtual2020
- A phase 2a study of the LSD1 inhibitor img-7289 (bomedemstat) for the treatment of myelofibrosis.American Society of Hematology, Orlando, FL2019
- Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.Blood Adv. 2020; 4: 5336-5342
- PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-Mutant MPN.Cancer Discov. 2020; 10: 1742-1757
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Nat Rev Drug Discov. 2014; 13: 673-691
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Blood. 2009; 114: 5024-5033
- Efficacy of vorinostat in a murine model of polycythemia vera.Blood. 2012; 119: 3779-3789
- JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.Clin Cancer Res. 2013; 19: 6230-6241
- A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.Leuk Lymphoma. 2019; 60: 1767-1774
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post- polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).Br J Haematol. 2013; 161: 68-75
- HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Blood. 2020; 135: 191-207
Article info
Publication history
Published online: February 04, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
